We are live on ! Find out more
GCP

GSA Capital Partners Portfolio holdings

AUM $1.59B
1-Year Est. Return 39.81%
This Fund
S&P 500
This Quarter Est. Return
-17.67%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$666M
AUM Growth
-$78.6M
Cap. Flow
+$47.8M
Cap. Flow %
7.17%
Top 10 Hldgs %
3.73%
Holding
1,985
New
628
Increased
360
Reduced
345
Closed
644

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$3.83M
2
EEM icon
iShares MSCI Emerging Markets ETF
EEM
+$3M
3
TECK icon
Teck Resources
TECK
+$2.87M
4
MODV
ModivCare
MODV
+$2.67M
5
G icon
Genpact
G
+$2.6M

Top Sells

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$3.07M
2
CHS
Chicos FAS, Inc.
CHS
+$2.68M
3
KRE icon
State Street SPDR S&P Regional Banking ETF
KRE
+$2.45M
4
CXT icon
Crane NXT
CXT
+$2.44M
5
ATCO
Atlas Corp.
ATCO
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 18.12%
2 Technology 15.11%
3 Consumer Discretionary 12.76%
4 Industrials 12.53%
5 Financials 11.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AOS icon
1376
A.O. Smith
AOS
$8.7B
– –
-7,372
Closed -$471K
APLS
1377
DELISTED
Apellis Pharmaceuticals
APLS
– –
-17,303
Closed -$879K
APTV icon
1378
Aptiv
APTV
$10.3B
– –
-3,023
Closed -$362K
AQMS icon
1379
Aqua Metals
AQMS
$10.2M
– –
-72
Closed -$22K
AQST icon
1380
Aquestive Therapeutics
AQST
$494M
– –
-34,769
Closed -$91K
ARDX icon
1381
Ardelyx
ARDX
$988M
– –
-589,576
Closed -$631K
ARI
1382
Apollo Commercial Real Estate
ARI
$885M
– –
-32,488
Closed -$453K
ARQT icon
1383
Arcutis Biotherapeutics
ARQT
$3.18B
– –
-27,851
Closed -$536K
ASIX icon
1384
AdvanSix
ASIX
$444M
– –
-25,168
Closed -$1.29M
ASMB icon
1385
Assembly Biosciences
ASMB
$529M
– –
-11,320
Closed -$280K
ATAI icon
1386
AtaiBeckley Inc
ATAI
$2.68B
– –
-23,935
Closed -$122K
ATEN icon
1387
A10 Networks
ATEN
$1.93B
– –
-72,654
Closed -$1.01M
ATLC icon
1388
Atlanticus Holdings
ATLC
$1.51B
– –
-7,175
Closed -$372K
ATNI icon
1389
ATN International
ATNI
$492M
– –
-16,135
Closed -$643K
ATOS icon
1390
Atossa Therapeutics
ATOS
$23.5M
– –
-4,415
Closed -$83K
ATRA icon
1391
Atara Biotherapeutics
ATRA
$76.1M
– –
-579
Closed -$134K
AUTL
1392
Autolus Therapeutics
AUTL
$562M
– –
-11,869
Closed -$49K
AVY icon
1393
Avery Dennison
AVY
$13.4B
– –
-4,474
Closed -$778K
AWI icon
1394
Armstrong World Industries
AWI
$7.84B
– –
-19,308
Closed -$1.74M
AWR icon
1395
American States Water
AWR
$3.46B
– –
-7,652
Closed -$681K
AXDX
1396
DELISTED
Accelerate Diagnostics
AXDX
– –
-16,208
Closed -$233K
AXGN icon
1397
Axogen
AXGN
$2.5B
– –
-17,398
Closed -$138K
AXON
1398
Axon Enterprise
AXON
$46.4B
– –
-2,043
Closed -$281K
AXSM icon
1399
Axsome Therapeutics
AXSM
$10.9B
– –
-18,656
Closed -$772K
AZN icon
1400
AstraZeneca
AZN
$250B
– –
-2,214
Closed -$294K
54 55
56
57 58

Similar funds

NCL
Nishkama Capital LLC Dorado, Puerto Rico $1.58B AUM 123.32% 1-Year Est. Return
DG
DigitalBridge Group Boca Raton, Florida $1.58B AUM 62.54% 1-Year Est. Return
VNT
Vanguard National Trust Malvern, Pennsylvania $1.59B AUM
SS
Sunbelt Securities Houston, Texas $1.58B AUM 28.96% 1-Year Est. Return
GWANC
Guardian Wealth Advisors (North Carolina) Raleigh, North Carolina $1.59B AUM 15.17% 1-Year Est. Return
LCM
Lakewood Capital Management New York $1.58B AUM 0.92% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
FDCP
Foster Dykema Cabot & Partners Waltham, Massachusetts $1.57B AUM 20.41% 1-Year Est. Return

GSA Capital Partners's Q2 2022 Portfolio in Review

As of Q2 2022, GSA Capital Partners held 1,985 positions worth $666M, down 11% from $745M the previous quarter. Its ten largest holdings account for 3.7% of the portfolio.

GSA Capital Partners deployed $47.8M of net new capital in Q2 2022, opening 628 new positions and adding to 360 existing holdings. Its largest new stake was Relay Therapeutics: 178,593 shares worth $2.99M.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Chicos FAS, Inc., an estimated $2.68M trimmed.

  • GSA Capital Partners's largest Q2 2022 buy was Relay Therapeutics: 178,593 shares worth $2.99M.
  • GSA Capital Partners added most to Genpact in Q2 2022, an estimated $2.6M increase.
  • GSA Capital Partners's biggest Q2 2022 reduction was Chicos FAS, Inc., cutting an estimated $2.68M.
  • GSA Capital Partners fully exited Amazon in Q2 2022, selling an estimated $3.07M.
  • GSA Capital Partners's ten largest holdings make up 3.7% of its $666M portfolio in Q2 2022.
  • GSA Capital Partners opened 628 new positions and closed 644 in Q2 2022.
  • GSA Capital Partners's portfolio value fell 11% quarter-over-quarter to $666M.

Based on GSA Capital Partners's 13F filing for Q2 2022, filed 9 Aug 2022.